Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study with a loading dose of clofazimine in adult patients with nontuberculous mycobacterial disease
2021-002062-40Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2021
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofazimine in nontuberculous mycobacteria infection, sponsored by Radboud University Medical Center. Primary endpoint: Pharmacokinetic parameters of clofazimine at day 28. Started Nov 2021; status: completed.
02
Drugs
clofazimine
03
Conditions
nontuberculous mycobacteria infection
Beyond the preview
Go deeper on 2021-002062-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002062-40.